Peptide vaccines usable for hypercholesterolemia related diseases
US-2024197844-A1 · Jun 20, 2024 · US
US2016304571A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016304571-A1 |
| Application number | US-201615199392-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jun 30, 2016 |
| Priority date | Mar 24, 2010 |
| Publication date | Oct 20, 2016 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention relates to a method of modifying a specific lysine residue in a polypeptide comprising at least two lysine residues, said method comprising (a) providing a polypeptide comprising a target lysine residue protected by a first protecting group, and at least one further lysine residue; (b) treating the polypeptide to protect said further lysine residue(s), wherein the protecting group for said further lysine residues is different to the protecting group for the target lysine residue; (c) selectively deprotecting the target lysine residue; and (d) modifying the deprotected lysine residue of (c).
Opening claim text (preview).
1 . A method of modifying a specific lysine residue in a ubiquitin polypeptide comprising at least two lysine residues, said method comprising: (a) providing a ubiquitin polypeptide comprising a target lysine residue protected by a first protecting group, and at least one further lysine residue, wherein the ubiquitin polypeptide comprising the target lysine group is provided by genetically incorporating the target lysine residue protected by the first protecting group into the ubiquitin polypeptide chain during its translation by (i) providing a nucleic acid encoding the ubiquitin polypeptide which nucleic acid comprises an orthogonal codon encoding the target lysine; and (ii) translating said nucleic acid in the presence of an orthogonal tRNA synthetase/tRNA pair capable of recognising said orthogonal codon and incorporating said target lysine residue protected by a first protecting group into the ubiquitin polypeptide chain; (b) treating the ubiquitin polypeptide to protect said further lysine residue(s), wherein the protecting group for said further lysine residues is different to the protecting group for the target lysine residue; (c) selectively deprotecting the target lysine residue; and (d) modifying the deprotected lysine residue of (c). 2 . A method according to claim 1 wherein said orthogonal codon comprises TAG, said tRNA comprises MbtRNA CUA and said tRNA synthetase comprises MbPylRS. 3 . A method according to claim 1 , wherein the target lysine residue protected by a first protecting group is Nε-(t-butyloxycarbonyl)-L-lysine. 4 . A method according to claim 1 , wherein the protecting group for said further lysine residues is N-(benzyloxycarbonyloxy) succinimide (Cbz-Osu). 5 . A method according to claim 1 wherein step (b) comprises treating the polypeptide with N-(benzyloxycarbonyloxy) succinimide (Cbz-OSu) in basic DMSO. 6 . A method according to claim 1 wherein step (c) comprises treating the polypeptide with trifluoroacetic (TFA) acid in water. 7 . A method according to claim 1 wherein the modification of step (d) is carried out on the ε-amino group of the target lysine residue. 8 . A method according to claim 1 wherein multiple modifications are made to the target lysine in step (d). 9 . A method according to claim 1 further comprising the step (e) deprotecting said further lysine residue(s). 10 . A method according to claim 1 , wherein the modification of step (d) is the covalent linkage of a further polypeptide chain to the target lysine. 11 . A method according to claim 10 wherein the further polypeptide chain is ubiquitin. 12 . The method according to claim 1 , wherein steps (c)-(d) are repeated to produce a chain of polypeptides joined by covalent linkages through lysine residues. 13 . A method of modifying a specific lysine residue in a ubiquitin polypeptide comprising at least two lysine residues, said method comprising: (a) providing a ubiquitin polypeptide comprising a target lysine residue protected by a first protecting group, and at least one further lysine residue, wherein the ubiquitin polypeptide comprising the target lysine group is provided by genetically incorporating the target lysine residue protected by the first protecting group into the ubiquitin polypeptide chain during its translation by (i) providing a nucleic acid encoding the ubiquitin polypeptide which nucleic acid comprises an orthogonal codon encoding the target lysine; and (ii) translating said nucleic acid in the presence of an orthogonal tRNA synthetase/tRNA pair capable of recognising said orthogonal codon and incorporating said target lysine residue protected by a first protecting group into the ubiquitin polypeptide chain; (b) treating the ubiquitin polypeptide to protect said further lysine residue(s), wherein the protecting group for said further lysine residues is different to the protecting group for the target lysine residue; (c) selectively deprotecting the target lysine residue; and (d) modifying the deprotected target lysine by activating thioester by conversion to N-hydroxysuccinimidyl ester in the presence of Ag(I), adding a polypeptide to be joined to the target lysine; and incubating to allow formation of a specific isopeptide bond. 14 . A ubiquitin polypeptide comprising at least two lysine residues, wherein a single target lysine residue in the ubiquitin polypeptide lacks a protecting group and the remaining lysine residues in the ubiquitin polypeptide comprise a protecting group. 15 . A ubiquitin polypeptide according to claim 15 produced according to claim 1 . 16 . A ubiquitin polypeptide according to claim 15 , wherein the ubiquitin polypeptide comprises an additional polypeptide linked to the ubiquitin polypeptide through the target lysine residue. 17 . A ubiquitin polypeptide according to claim 17 , wherein the target lysine residue is K6 or K29. 18 . A ubiquitin polypeptide according to claim 15 , wherein the target lysine residue is not on a terminal end of the ubiquitin polypeptide.
having a known sequence of two or more amino acids, e.g. glutathione · CPC title
for omega-amino or -guanidino functions · CPC title
by covalent attachment of amino acids or peptide residues · CPC title
for heterocyclic side chains · CPC title
derived from animal tissue · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.